Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Shuhang Wang"'
Autor:
Shuhang Wang, Dawei Wu, Jun Wang, Hong Fang, Jie He, Huiyao Huang, Ning Li, Yu Tang, Hui-lei Miao, Binghe Xu, Qi Lei
Publikováno v:
Journal of the National Cancer Center, Vol 1, Iss 4, Pp 147-152 (2021)
Objectives: To describe and compare the research and development (R&D) pipeline of cancer new drugs and newly approved drugs in China and the USA in 2020, thus to provide decision-making evidence for related stakeholders. Methods: Clinical trials and
Autor:
Ni Li, Fan Zhang, Jie He, Shuhang Wang, Zhijie Wang, Ning Li, Shugeng Gao, Wenqiang Wei, Nan Bi
Publikováno v:
Journal of Thoracic Oncology. 15:1567-1576
Autor:
Zicheng Yu, Anqi Yu, Huiyao Huang, Yuan Fang, Chao Zhang, Chao Sun, Shuhang Wang, Yi Huang, Ying Bai, Hong Fang, Ning Li, Qi Fan, Yue Yu, Zaixian Tai, Dawei Wu, Changxi Wang
Publikováno v:
Journal of Genetics and Genomics. 47:397-401
Autor:
Xue Yang, Jun Zhao, Hanxiao Chen, Yujia Chi, Tongtong An, Yuyan Wang, Jie Wang, Minglei Zhuo, Zhijie Wang, Jianchun Duan, Qiuping Liang, Jia Zhong, Shuhang Wang
Publikováno v:
Thoracic Cancer, Vol 11, Iss 5, Pp 1149-1159 (2020)
Thoracic Cancer
Thoracic Cancer
Background Previous trials have suggested that elderly patients with non‐small‐cell lung cancer (NSCLC) could benefit from nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel). Real‐world data on the elderly Chinese population are lacking
Autor:
Bing Wang, Jun Zhao, Fan Zhang, Xiuli Tao, Jie He, Shun He, Ning Wu, Yun Ling, Shugeng Gao, Nan Sun, Dali Wang, Fang Lv, Kai Su, S. Gao, Kang Shao, Wendong Lei, Shuhang Wang, Yue Yu, Dawei Wu, Qi Xue, Wei Tang, Lei Zhang, Zhijie Wang, Fengwei Tan, Liang Zhao, Ziran Zhao, Ning Li, Jianming Ying, Yibo Gao, Yousheng Mao, Chunjian Duan, Jie Wang
Publikováno v:
Journal of Thoracic Oncology. 15:816-826
Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is limited. This is a phase 1b study to evaluate the safety and outcome of PD-1 inhibitor
Publikováno v:
Genes & Diseases
Genes and Diseases, Vol 9, Iss 1, Pp 245-251 (2022)
Genes and Diseases, Vol 9, Iss 1, Pp 245-251 (2022)
TP53 mutations was reported to be correlated to the efficacy of program death-1 (PD-1) and program death ligand-1 (PD-L1). The role of co-mutations of TP53 with other recurrently mutated genes in outcome of anti-PD-(L)1 treatment for non-small cell l
Autor:
Zhengyi Zhao, Jun Zhao, Yanhua Tian, Rui Wan, Yuezong Bai, Kailun Fei, Hua Dong, Lei Xiong, Zhijie Wang, Minglei Zhuo, Jie Wang, Hua Bai, Bo Zhu, Yuzi Zhang, Depei Huang, Jianchun Duan, Shangli Cai, Guoqiang Wang, Di Wang, Chan Gao, Xingsheng Hu, C. Xu, Shuhang Wang, Xiaochen Zhao, Wenxian Wang, Jianguo Sun, Chuang Qi, Jiefei Han, Jing Zhao, Mengli Huang, Jiachen Xu, Junling Li, Xin Wang
Publikováno v:
Journal of Thoracic Oncology. 15:556-567
Blood-based tumor mutational burden (bTMB) has been studied to identify patients with NSCLC who would benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death ligand 1 (anti-PD-L1) therapies. However, it failed to predic
Autor:
Zewei Zhang, Shugeng Gao, Xiuli Tao, Jie Wang, Ning Wu, Shuhang Wang, Wei Tang, Jie He, Jianming Ying, Zhijie Wang, Ning Li, Yun Ling
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
Purpose Investigate whether 18F-FDG PET-CT has the potential to predict the major pathologic response (MPR) to neoadjuvant sintilimab in resectable NSCLC patients, and the potential of sifting patients who probably benefit from immunotherapy. Methods
Autor:
Yanhua Tian, Yuqi Wang, Di Wang, Jiefei Han, Zhijie Wang, Zhimin Lu, Rui Wan, Kailun Fei, Jie Wang, Shuhang Wang, Si Chen, Zhuoran Yao, Xin Wang, Jianchun Duan, Hua Bai
Publikováno v:
Cancer Immunology Research. 8:146-154
T-cell receptor (TCR)–based biomarkers might predict patient response to immune checkpoint blockade (ICB) but need further exploration and validation for that use. We sequenced complementarity-determining region 3 of TCRβ chains isolated from PD-1
Publikováno v:
Lung Cancer. 135:116-122
Objectives The utility of malignant pleural effusion (MPE) as a source for determining EGFR mutations to guide EGFR TKI therapy in advanced adenocarcinoma of the lung remains unclear. This study compared MPE, plasma and tumor tissues as sources of bi